Drug Development

Welcome to the 'Drug Development' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'Drug Development'.

Latest blogosphere posts tagged “Drug Development”

• A Week of Woe for Genzyme, A CPR App for Your iPhone, A Better Treatment for Opioid Dependence, and More Boston-Area Life Sciences News

  
  Xconomy — Authority: 712
  Life Sciences , Roundup , Drug Development Wade Roush wrote: Believe it or not, the troubles besetting Genzyme (NASDAQ: GENZ ) were not the only life science stories coming out of the Boston area this week, although they sure grabbed most of the attention. So let’s get them all out of the way first: ...
  3 days ago

• On The Couch… Weekend Reading

  
  Pharmalot — Authority: 584
  Hello, everyone. In between raking leaves, hanging with the short people and walking our faithful friend, we thought it might be helpful to offer you a few minutes of interesting reading. As always, there is much to track. Just the same, we have some errands to run shortly - what the weekend be without running from ...
  1 week ago

• Right Brains Wanted: Sanofi-Aventis Wants to Tap the Creative Genius of Boston-Area Biotechs

  
  Xconomy — Authority: 712
  Life Sciences , Drug Development , biotechnology Ryan McBride wrote: Sanofi-Aventis (NYSE: SNY ) hosted a large event at its R&D site in Cambridge, MA, yesterday to make its pitch for why Boston-area biotech companies should want to form partnerships with the French drug giant. It was an ...
  1 week ago

• Good Things in Threes: Trius Therapeutics Files for IPO to Fund Phase 3 Clinical Trials, Marks San Diego’s Third IPO Filing

  
  Xconomy — Authority: 712
  IPO , Drug-Resistant Infections , Drug Development Bruce V. Bigelow wrote: San Diego’s Trius Therapeutics , a venture-backed biotech developing a new antibiotic for treating acute and life-threatening bacterial infections, submitted a regulatory filing Friday to raise as much as $86 million in an ...
  1 week ago

• Gilead (GILD): New potential in 4-in-1 HIV drug

  
  BloggingStocks — Authority: 665
  Filed under: Newsletters , Gilead Sciences (GILD) , Stocks to Buy " Gilead Sciences (NASDAQ: GILD ) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe . The contributing editor to Personal Finance explains, "Already the market ...
  2 weeks ago

• GAO Issues Report on Surrogate Endpoint Accelerated Approvals; Calls for Enhanced Oversight

  
  FDA Law Blog — Authority: 497
  By Kurt R. Karst –       A recent report from the Government Accountability Office (“GAO”), titled “FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints,” finds that weaknesses in FDA’s monitoring and enforcement process have hampered the Agency’s ability ...
  2 weeks ago

• Amylin Forms Global Alliance in Obesity Drug Development; TEDMED’s Show Will Go On, Sequenom Sued for Civil Fraud, & More San Diego Biotech News

  
  Xconomy — Authority: 712
  Roundup , Life Sciences , diabetes Bruce V. Bigelow wrote: TEDMED had Martha, Goldie, and other celebrity speakers, but San Diego-based Amylin Pharmaceuticals broke this week’s big news when it signed up a big Japanese partner to develop its line of obesity drugs. It’s all part of your regular dose of ...
  2 weeks ago

• Tiny injector to speed development of new, safer, cheaper drugs

  
  Science Blog - Science news straight from the source — Authority: 647
  Its no bigger than a stamp packet but it has the potential to allow rapid development of a new generation of drugs and genetic engineering organisms, and to better control in-vitro fertilization.
  2 weeks ago

• Supreme Court to Decide Whether an FDA Warning Letter Starts the Statute of Limitations in a Securities Fraud Case

  
  FDA Law Blog — Authority: 497
  By Carrie S. Martin – On November 30, 2009, the United States Supreme Court will hear oral argument in Merck & Co. v. Reynolds , No. 08-905 , a securities class action.  The case concerns the standard of inquiry required to start the clock running on the statute of limitations in a private securities ...
  2 weeks ago

• HPM Posts Summary of H.R. 3962 Provisions Directly Affecting Drug and Device Manufacturers

  
  FDA Law Blog — Authority: 497
  By Alan M. Kirschenbaum & Kurt R. Karst – Last Thursday we reported on the release by the House of H.R. 3962, the health care reform bill that will soon be considered on the House floor.  As we have done with other health care reform proposals, we have prepared a summary of the provisions of H.R. 3962 ...
  2 weeks ago

• FDA’s Letter to P&G over VICKS DayQuil and NyQuil Plus Vitamin C is Back (for now?)

  
  FDA Law Blog — Authority: 497
  By Ricardo Carvajal – FDA has again posted a warning letter to Procter and Gamble stating that the company’s VICKS DayQuil Plus Vitamin C and VICKS NyQuil Plus Vitamin C are unapproved new drugs and are  misbranded.  The letter states that, when “drug and dietary ingredients are combined into a single ...
  2 weeks ago

• Seventh Circuit Affirms Dismissal of FDA-related Lanham Act Case and Quotes William Blake to Boot

  
  FDA Law Blog — Authority: 497
  JP Ellison – In March of 2008, we reported on a Wisconsin federal district court opinion that dismissed a plaintiff’s Lanham Act claim against three manufacturers of generic prescription drug products.  On October 29, 2008, the Seventh Circuit issued a decision in an appeal of that same case.  As we noted ...
  3 weeks ago

• Report Recommends a Variety of “Push” and “Pull” Mechanisms to Incentivize New Antibiotic Drug Development

  
  FDA Law Blog — Authority: 497
  By Kurt R. Karst –       A recent report  issued by the London School of Economics and Political Science (“LSEPS”), and commissioned by the Swedish government, urges governments to create new incentives to promote the research and development of antibiotics in light of the growing concern over ...
  3 weeks ago

• Affordable Health Care for America Act Introduced in House

  
  FDA Law Blog — Authority: 497
  By Alan M. Kirschenbaum & Kurt R. Karst – Earlier today, House Speaker Nancy Pelosi (D-CA) unveiled the Affordable Health Care for America Act ( H.R. 3962 ).  The bill, which is the latest version of the House’s healthcare reform proposal and the one that will go to the House floor, is almost 2,000 ...
  3 weeks ago

• TGen seeks emergency FDA approval of new swine flu test

  
  Science Blog - Science news straight from the source — Authority: 647
  FLAGSTAFF, Ariz. -- Oct.
  3 weeks ago

• Update – Bill Introduced to Give FDA Greater Power to Remove Problem Researchers

  
  FDA Law Blog — Authority: 497
  By Susan J. Matthees – On October 27th, on the heels of the release of the Government Accountability Office’s report in which the Office is critical of FDA’s oversight of clinical investigators (see our previous post ), Rep. Joe Barton (R-TX) introduced H.R.3932 , the Strengthening of FDA Integrity Act of ...
  3 weeks ago

• Celgene (CELG): Bet on biotech for offense and defense

  
  BloggingStocks — Authority: 665
  Filed under: Newsletters , Stocks to Buy "I am recommending Celgene (NASDAQ: CELG ) as part of an offense-defense thesis," says Ian Wyatt . In Top Stock Insights , he reviews the leading biotechnology company. Wyatt explains, "Celgene engages in the discovery of therapies designed to treat cancer and immune ...
  3 weeks ago

• New GAO Report - Oversight of Clinical Investigators

  
  FDA Law Blog — Authority: 497
  By Susan J. Matthees – Last month the Government Accounting Office ("GAO") published a new report ("GAO report") on the oversight of clinical investigators.  The report is critical of FDA’s oversight of clinical investigators, citing numerous instances where FDA did not take timely action to respond to ...
  3 weeks ago

• Why antidepressants dont work for so many

  
  Science Blog - Science news straight from the source — Authority: 647
  CHICAGO --- More than half the people who take antidepressants for depression never get relief.
  4 weeks ago

• California Court Denies Preliminary Injunction in Lanham Act Case Concerning Unapproved Colchicine Drugs

  
  FDA Law Blog — Authority: 497
  By Kurt R. Karst –    Earlier this week, the U.S. District Court for the Central District of California denied  a Motion for Preliminary Injunction  filed by Mutual Pharmaceutical Company, Inc. (“Mutual”), and AR Scientific, Inc. and AR Holding Company, Inc. (“AR”) in a Lanham Act case concerning ...
  4 weeks ago

Comments about Drug Development